Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Via Pharmaceuticals, a biotechnology company, has announced exclusive, worldwide licensing agreements with Roche for two sets of compounds.
Subscribe to our email newsletter
The first was for Roche’s thyroid hormone receptor (THR) beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes. The second was for multiple compounds from Roche’s preclinical diacylglycerol acyl transferase 1 (DGAT1) metabolic disorders program.
Under the terms of the agreements, Via will assume control of all development and commercialization of the compounds, and will own exclusive worldwide rights for all potential indications. The agreements provide for milestone payments for development and royalties upon commercialization.
Lawrence Cohen, CEO of Via Pharmaceuticals, said: “The THR beta agonist candidate and the DGAT1 program are natural fits for Via, and build on the company’s cardiovascular inflammation programs. We believe that these compounds address other critical underlying causes of cardiovascular disease: hyperlipidemias and metabolic disorders including diabetes.
“In addition, Rebecca Taub, our senior vice president of R&D, has significant experience in heading up development programs in metabolic diseases, and previously oversaw both the THR beta agonist and DGAT1 programs at Roche. We look forward to moving the THR beta agonist into clinical development.”